Sol-Gel Technologies Announces Closing of Additional $5.0 Million Investment
April 13, 2020 07:05 ET
|
Sol-Gel Technologies Ltd.
Investment is for ordinary shares and warrants to purchase ordinary shares at a combined price of $11 per ordinary share and accompanying warrants to purchase 0.80 of an ordinary share Investment...
UPDATE -- Sol-Gel Technologies to Present at Upcoming 2020 Solebury Trout Virtual Investor Conference
March 25, 2020 10:58 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, March 25, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel Technologies Reports Full Year 2019 Financial Results and Corporate Update
March 24, 2020 16:05 ET
|
Sol-Gel Technologies Ltd.
Top-line generic product revenue of $22.8 million in fiscal 2019New Drug Applications for Epsolay® and Twyneo® remain on track for the second quarter and second half 2020, respectively NESS ZIONA,...
Sol-Gel Technologies to Report Full Year 2019 Financial Results and Corporate Update
March 19, 2020 17:45 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, March 19, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel to Present at the Cowen 40th Annual Health Care Conference
February 19, 2020 09:25 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing...
Sol-Gel Announces Pricing of Public Offering of Ordinary Shares and Warrants to Purchase Ordinary Shares
February 14, 2020 06:45 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel Announces Positive Topline Results from Open-Label, Long-Term Safety Study of Epsolay® for Treatment up to 52 Weeks
February 13, 2020 16:05 ET
|
Sol-Gel Technologies Ltd.
Successful topline results, strengthens Epsolay’s long-term safety and tolerability profile in the treatment of papulopustular rosacea Results pave the way for NDA submission in the second quarter of...
Sol-Gel Provides Product Pipeline Updates and Anticipated Milestones for 2020
February 05, 2020 07:05 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”) a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel Announces Presentation of Data for its Topical Product Candidates for Acne and Rosacea at the 16th Annual Maui Derm for Dermatologists 2020 Meeting
January 21, 2020 16:05 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”) today announced the presentation of results from the Company’s Phase 3...
Sol-Gel Hosts Investor Call to Discuss Positive Results from Twyneo® Phase 3 Program in Acne Vulgaris
January 08, 2020 07:00 ET
|
Sol-Gel Technologies Ltd.
Conference call with Sol-Gel management and U.S. key opinion leader today at 8:00 a.m. Eastern time NESS ZIONA, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL)...